ARID2 mutation status had the most significant impact in any gene, as SCLC patients with wild-type ARID2 demonstrated worse OS than the patients with mutant ARID2 (HR 3.664, 95% CI 1.507–8.906, P=0.055) (Figure 4B). This evidence concerns the gene ARID2 and small cell lung carcinoma.